Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387497492> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4387497492 abstract "Recent studies raise concern for increased risk of major adverse cardiovascular events (MACE) with Janus kinase inhibitors (JAKi) used to treat immune-mediated inflammatory disorders (IMIDs). We aimed to examine MACE risk with licensed biologics and small molecules used commonly between IMIDs: inflammatory bowel disease, rheumatoid arthritis, psoriasis/psoriatic arthritis, and ankylosing spondylitis.Data were obtained from systematic searches (from inception to May 31, 2022) in PubMed, Embase, Ovid Medline, Scopus, Cochrane Central, and Clinicaltrials.gov. Studies that assessed a pre-defined MACE (myocardial infarction, cerebrovascular accident, unstable angina, cardiovascular death, or heart failure) risk in those ≥18 years with IMIDs treated with anti-interleukin (IL)-23 antibodies, anti-IL-12/23, anti-tumor necrosis factor-alpha antibodies (anti-TNF-α) or JAKi were included in a network meta-analysis using a random-effects model with pooled odds ratios (ORs) reported with 95% credible intervals (CrIs) by drug class and disease state.Among 3,528 studies identified, 40 (36 randomized controlled trials [RCTs] and 4 cohort studies) were included in the systematic review, comprising 126,961 patients with IMIDs. Based on network meta-analysis of RCTs, regardless of disease state, anti-TNF-α (OR, 2.49; CrI: 1.14-5.62), JAKi (OR, 2.64; CrI: 1.26-5.99), and anti-IL-12/23 (OR, 3.15; CrI: 1.01-13.35) were associated with increased MACE risk compared with placebo. There was no significant difference in the magnitude of the MACE risk between classes or based on IMID type.Anti-IL-12/23, JAKi, and anti-TNF-α were associated with higher risk of MACE compared with placebo. The magnitude of the increased MACE risk was not different by IMID type. These results require confirmation in larger prospective studies." @default.
- W4387497492 created "2023-10-11" @default.
- W4387497492 creator A5009302642 @default.
- W4387497492 creator A5030317845 @default.
- W4387497492 creator A5031260848 @default.
- W4387497492 creator A5034738993 @default.
- W4387497492 creator A5065557396 @default.
- W4387497492 creator A5081792767 @default.
- W4387497492 creator A5093036034 @default.
- W4387497492 creator A5093036035 @default.
- W4387497492 date "2023-10-01" @default.
- W4387497492 modified "2023-10-13" @default.
- W4387497492 title "Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis" @default.
- W4387497492 doi "https://doi.org/10.1016/j.cgh.2023.09.033" @default.
- W4387497492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37821035" @default.
- W4387497492 hasPublicationYear "2023" @default.
- W4387497492 type Work @default.
- W4387497492 citedByCount "0" @default.
- W4387497492 crossrefType "journal-article" @default.
- W4387497492 hasAuthorship W4387497492A5009302642 @default.
- W4387497492 hasAuthorship W4387497492A5030317845 @default.
- W4387497492 hasAuthorship W4387497492A5031260848 @default.
- W4387497492 hasAuthorship W4387497492A5034738993 @default.
- W4387497492 hasAuthorship W4387497492A5065557396 @default.
- W4387497492 hasAuthorship W4387497492A5081792767 @default.
- W4387497492 hasAuthorship W4387497492A5093036034 @default.
- W4387497492 hasAuthorship W4387497492A5093036035 @default.
- W4387497492 hasConcept C126322002 @default.
- W4387497492 hasConcept C156957248 @default.
- W4387497492 hasConcept C197934379 @default.
- W4387497492 hasConcept C2776260265 @default.
- W4387497492 hasConcept C2777402515 @default.
- W4387497492 hasConcept C2777575956 @default.
- W4387497492 hasConcept C2778886723 @default.
- W4387497492 hasConcept C2780739214 @default.
- W4387497492 hasConcept C45393284 @default.
- W4387497492 hasConcept C500558357 @default.
- W4387497492 hasConcept C71924100 @default.
- W4387497492 hasConcept C95190672 @default.
- W4387497492 hasConceptScore W4387497492C126322002 @default.
- W4387497492 hasConceptScore W4387497492C156957248 @default.
- W4387497492 hasConceptScore W4387497492C197934379 @default.
- W4387497492 hasConceptScore W4387497492C2776260265 @default.
- W4387497492 hasConceptScore W4387497492C2777402515 @default.
- W4387497492 hasConceptScore W4387497492C2777575956 @default.
- W4387497492 hasConceptScore W4387497492C2778886723 @default.
- W4387497492 hasConceptScore W4387497492C2780739214 @default.
- W4387497492 hasConceptScore W4387497492C45393284 @default.
- W4387497492 hasConceptScore W4387497492C500558357 @default.
- W4387497492 hasConceptScore W4387497492C71924100 @default.
- W4387497492 hasConceptScore W4387497492C95190672 @default.
- W4387497492 hasLocation W43874974921 @default.
- W4387497492 hasLocation W43874974922 @default.
- W4387497492 hasOpenAccess W4387497492 @default.
- W4387497492 hasPrimaryLocation W43874974921 @default.
- W4387497492 hasRelatedWork W1984540686 @default.
- W4387497492 hasRelatedWork W2066459214 @default.
- W4387497492 hasRelatedWork W2410643200 @default.
- W4387497492 hasRelatedWork W2503659988 @default.
- W4387497492 hasRelatedWork W2766717228 @default.
- W4387497492 hasRelatedWork W2929695502 @default.
- W4387497492 hasRelatedWork W2979840877 @default.
- W4387497492 hasRelatedWork W3001590743 @default.
- W4387497492 hasRelatedWork W3015942815 @default.
- W4387497492 hasRelatedWork W3035443521 @default.
- W4387497492 isParatext "false" @default.
- W4387497492 isRetracted "false" @default.
- W4387497492 workType "article" @default.